Detalhe da pesquisa
1.
Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy.
Breast Cancer Res Treat
; 199(2): 231-241, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36947277
2.
Retrospective study on the effectiveness of medroxyprogesterone acetate in the treatment of ER-positive/HER2-negative post-menopausal advanced breast cancer: an additional analysis of the JBCRG-C06 Safari study.
Jpn J Clin Oncol
; 53(3): 203-211, 2023 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36484305
3.
Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial.
Lancet Oncol
; 23(5): 636-649, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35405087
4.
Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS).
Cancer Sci
; 113(9): 3169-3179, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35754298
5.
Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative postmenopausal breast cancer: an ad hoc analysis of the JBCRG-C06 Safari study.
Jpn J Clin Oncol
; 52(6): 545-553, 2022 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-35296894
6.
Anthracycline-containing regimens or taxane versus S-1 as first-line chemotherapy for metastatic breast cancer.
Br J Cancer
; 125(9): 1217-1225, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34480096
7.
Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19).
Int J Clin Oncol
; 26(7): 1229-1236, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33891194
8.
Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study.
Br J Cancer
; 122(12): 1747-1753, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32238920
9.
A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer.
Breast Cancer Res Treat
; 180(3): 715-724, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-32170634
10.
Type 2 diabetes susceptibility genes on mouse chromosome 11 under high sucrose environment.
BMC Genet
; 21(1): 81, 2020 07 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-32703163
11.
Omitting surgery for early breast cancer showing clinical complete response to primary systemic therapy.
Jpn J Clin Oncol
; 50(6): 629-634, 2020 Jun 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32378709
12.
[A Case of Progressive Sarcomatoid Renal Cell Carcinoma Treated with Second-Line Nivolumab after Surgery].
Hinyokika Kiyo
; 66(8): 265-268, 2020 Aug.
Artigo
em Japonês
| MEDLINE | ID: mdl-32882123
13.
Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.
Breast Cancer Res Treat
; 173(1): 123-133, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30242578
14.
Multicenter Phase II Study of Intraoperative Radiotherapy of Early Breast Cancer: Ipsilateral Tumor Recurrence.
Ann Surg Oncol
; 26(8): 2428-2434, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-30993410
15.
Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis.
Breast Cancer Res Treat
; 167(1): 81-87, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28895005
16.
A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study.
Jpn J Clin Oncol
; 48(9): 855-859, 2018 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30020510
17.
Hormonal Therapy Resistant Estrogen-receptor Positive Metastatic Breast Cancer Cohort (HORSE-BC) Study : Current Status of Treatment Selection in Japan.
Acta Med Okayama
; 72(4): 369-374, 2018 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-30140084
18.
Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19).
Int J Clin Oncol
; 27(11): 1793, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36166110
19.
Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19).
Int J Clin Oncol
; 26(7): 1237, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34043103
20.
Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis.
Breast Cancer Res Treat
; 149(1): 277-84, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25528021